PMID- 23956007
OWN - NLM
STAT- MEDLINE
DCOM- 20140611
LR  - 20141120
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 29
IP  - 8
DP  - 2013 Nov
TI  - Oral hypoglycaemic agents and the development of non-fatal cardiovascular events 
      in patients with type 2 diabetes mellitus.
PG  - 673-9
LID - 10.1002/dmrr.2444 [doi]
AB  - AIMS: This study aimed to assess the risk of non-fatal cardiovascular events 
      among patients with type 2 diabetes mellitus (T2DM) who are taking metformin, 
      glimepiride or glyburide. MATERIALS AND METHODS: Using the National Health 
      Insurance Research database in Taiwan, this retrospective cohort study identified 
      1159 patients with newly diagnosed T2DM from 1998 to 2007, 30 years and older and 
      without a history of cardiovascular disease at baseline. Patients with cancer, 
      liver cirrhosis or chronic kidney disease were excluded. On the basis of 
      prescription, patients were grouped into three medication subcohorts: metformin 
      (N = 595), glimepiride (N = 234) or glyburide (N = 330) monotherapy for 100% of 
      the follow-up period without any oral anti-diabetic agents added or changed, by 
      the end of 2009. Incidence and hazard ratios of non-fatal cardiovascular events 
      including coronary artery disease, peripheral artery disease, stroke and heart 
      failure among these three subcohorts were compared. RESULTS: The overall 
      incidence of non-fatal cardiovascular events was the highest for patients taking 
      glyburide (169.1 per 1000 person-years), followed by for those taking glimepiride 
      and metformin (95.2 and 49.1 per 1000 person-years, respectively). Compared with 
      the adjusted hazard ratio for patients taking glyburide, the adjusted hazard 
      ratio for those taking glimepiride was 0.52 (95% CI 0.40-0.69) and for those 
      taking metformin was 0.31 (95% CI 0.24-0.40). CONCLUSIONS: T2DM patients taking 
      metformin and glimepiride are at lower risk of non-fatal cardiovascular events 
      than those taking glyburide.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
FAU - Hung, Yi-Chih
AU  - Hung YC
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, China 
      Medical University Hospital, Taichung, 40447, Taiwan; Department of Internal 
      Medicine, China Medical University, Taichung, 40447, Taiwan.
FAU - Lin, Che-Chen
AU  - Lin CC
FAU - Wang, Tzu-Yuan
AU  - Wang TY
FAU - Chang, Man-Ping
AU  - Chang MP
FAU - Sung, Fung-Chang
AU  - Sung FC
FAU - Chen, Ching-Chu
AU  - Chen CC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - 6KY687524K (glimepiride)
RN  - 9100L32L2N (Metformin)
RN  - SX6K58TVWC (Glyburide)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Cardiovascular Diseases/*epidemiology
MH  - Cohort Studies
MH  - Comorbidity
MH  - Coronary Disease
MH  - Diabetes Mellitus, Type 2/*drug therapy/*epidemiology
MH  - Dyslipidemias/epidemiology
MH  - Female
MH  - Glyburide/therapeutic use
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incidence
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Sulfonylurea Compounds/therapeutic use
MH  - Taiwan/epidemiology
OTO - NOTNLM
OT  - cardiovascular events
OT  - metformin
OT  - sulfonylurea
OT  - type 2 diabetes mellitus
EDAT- 2013/08/21 06:00
MHDA- 2014/06/12 06:00
CRDT- 2013/08/20 06:00
PHST- 2013/02/19 00:00 [received]
PHST- 2013/07/29 00:00 [revised]
PHST- 2013/07/31 00:00 [accepted]
PHST- 2013/08/20 06:00 [entrez]
PHST- 2013/08/21 06:00 [pubmed]
PHST- 2014/06/12 06:00 [medline]
AID - 10.1002/dmrr.2444 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2013 Nov;29(8):673-9. doi: 10.1002/dmrr.2444.